MedTrace Logo

A Study for Patients With Schizophrenia

NCT00520923 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 654

Last updated 2009-10-19

No results posted yet for this study

Summary

The purpose of this study is to test the hypothesis that 1 or more dose levels of LY2140023 given orally to patients with schizophrenia twice daily for 4 weeks will have significantly greater effect than placebo.

Conditions

Interventions

DRUG

LY2140023

80mg, PO (by mouth) BID (twice a day) for up to 4 weeks.

DRUG

LY2140023

40mg, PO (by mouth) BID (twice daily) for up to 4 weeks.

DRUG

LY2140023

20mg, PO (by mouth) BID (twice daily) for up to 4 weeks.

DRUG

LY2140023

5mg, PO (by mouth) BID (twice daily) for up to 4 weeks.

DRUG

Olanzapine

10mg, PO (by mouth) QPM (every evening) for the first 3 days, then 15mg PO QPM, for up to 4 weeks.

DRUG

Placebo

Taken PO (by mouth) QAM (every morning) for up to 4 weeks.

DRUG

Placebo

Taken PO (by mouth) BID (twice daily) for up to 4 weeks.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • Argentina
  • Austria
  • Croatia
  • Germany
  • Mexico
  • Portugal
  • Romania
  • Russia
  • South Africa

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00520923 on ClinicalTrials.gov